Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis

Susanne Matschurat, Sabine Blum, Rita Mitnacht-Kraus, Henry B P M Dijkman, Levent Kanal, Robert M W De Waal, Matthias Clauss

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tissue factor is the prime initiator of blood coagulation. Expression of tissue factor in tumor endothelial cells leads to thrombus formation, occlusion of vessels and development of hemorrhagic infarctions in the tumor tissue, often followed by regression of the tumor. Tumor cells produce endogenous vascular endothelial growth factor (VEGF), which sensitizes endothelial cells for systemically administered tumor necrosis factor α (TNF α) and synergistically enhances the TNF-induced expression of tissue factor. We have analyzed the pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells (HUVECS) after combined stimulation with TNF and VEGF. By using specific low molecular weight inhibitors, we demonstrated that protein kinase C (PKC), p44/42 and p38 mitogen-activated protein (MAP) kinases, and stress-activated protein kinase (JNK) are essentially involved in the induction of tissue factor. In contrast, the application of wortmannin, an inhibitor of phosphatidylinositol 3 (PI3)-kinase, led to strongly enhanced expression of tissue factor in TNF- and VEGF-treated cells, implicating a negative regulatory role for PI3-kinase. In vivo, the application of wortmannin promoted the formation of TNF-induced hemorrhages and intratumoral necroses in murine meth A tumors. The co-injection of wortmannin lowered the effective dose of applied TNF. Therefore, it is conceivable that the treatment of TNF-sensitive tumors with a combination of TNF and wortmannin will ensure the selective damage of the tumor endothelium and minimize the risk of systemic toxicity of TNF. TNF-treatment in combination with specific inhibition of PI3-kinase is a novel concept in anti-cancer therapy.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalInternational Journal of Cancer
Volume107
Issue number1
DOIs
StatePublished - Oct 20 2003

Fingerprint

Phosphatidylinositol 3-Kinase
Necrosis
Tumor Necrosis Factor-alpha
Thromboplastin
Neoplasms
Vascular Endothelial Growth Factor A
Endothelial Cells
Umbilical Cord
Human Umbilical Vein Endothelial Cells
Blood Coagulation
p38 Mitogen-Activated Protein Kinases
Heat-Shock Proteins
Protein Kinases
Infarction
Protein Kinase C
Endothelium
Thrombosis
Therapeutics
Molecular Weight

Keywords

  • Anti-tumor therapy
  • PI3-kinase
  • Tissue factor
  • Tumor necrosis factor
  • Vascular targeting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Matschurat, S., Blum, S., Mitnacht-Kraus, R., Dijkman, H. B. P. M., Kanal, L., De Waal, R. M. W., & Clauss, M. (2003). Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis. International Journal of Cancer, 107(1), 30-37. https://doi.org/10.1002/ijc.11345

Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis. / Matschurat, Susanne; Blum, Sabine; Mitnacht-Kraus, Rita; Dijkman, Henry B P M; Kanal, Levent; De Waal, Robert M W; Clauss, Matthias.

In: International Journal of Cancer, Vol. 107, No. 1, 20.10.2003, p. 30-37.

Research output: Contribution to journalArticle

Matschurat, S, Blum, S, Mitnacht-Kraus, R, Dijkman, HBPM, Kanal, L, De Waal, RMW & Clauss, M 2003, 'Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis', International Journal of Cancer, vol. 107, no. 1, pp. 30-37. https://doi.org/10.1002/ijc.11345
Matschurat S, Blum S, Mitnacht-Kraus R, Dijkman HBPM, Kanal L, De Waal RMW et al. Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis. International Journal of Cancer. 2003 Oct 20;107(1):30-37. https://doi.org/10.1002/ijc.11345
Matschurat, Susanne ; Blum, Sabine ; Mitnacht-Kraus, Rita ; Dijkman, Henry B P M ; Kanal, Levent ; De Waal, Robert M W ; Clauss, Matthias. / Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis. In: International Journal of Cancer. 2003 ; Vol. 107, No. 1. pp. 30-37.
@article{19c00417b43643e79cca6807bbd358a0,
title = "Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis",
abstract = "Tissue factor is the prime initiator of blood coagulation. Expression of tissue factor in tumor endothelial cells leads to thrombus formation, occlusion of vessels and development of hemorrhagic infarctions in the tumor tissue, often followed by regression of the tumor. Tumor cells produce endogenous vascular endothelial growth factor (VEGF), which sensitizes endothelial cells for systemically administered tumor necrosis factor α (TNF α) and synergistically enhances the TNF-induced expression of tissue factor. We have analyzed the pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells (HUVECS) after combined stimulation with TNF and VEGF. By using specific low molecular weight inhibitors, we demonstrated that protein kinase C (PKC), p44/42 and p38 mitogen-activated protein (MAP) kinases, and stress-activated protein kinase (JNK) are essentially involved in the induction of tissue factor. In contrast, the application of wortmannin, an inhibitor of phosphatidylinositol 3 (PI3)-kinase, led to strongly enhanced expression of tissue factor in TNF- and VEGF-treated cells, implicating a negative regulatory role for PI3-kinase. In vivo, the application of wortmannin promoted the formation of TNF-induced hemorrhages and intratumoral necroses in murine meth A tumors. The co-injection of wortmannin lowered the effective dose of applied TNF. Therefore, it is conceivable that the treatment of TNF-sensitive tumors with a combination of TNF and wortmannin will ensure the selective damage of the tumor endothelium and minimize the risk of systemic toxicity of TNF. TNF-treatment in combination with specific inhibition of PI3-kinase is a novel concept in anti-cancer therapy.",
keywords = "Anti-tumor therapy, PI3-kinase, Tissue factor, Tumor necrosis factor, Vascular targeting",
author = "Susanne Matschurat and Sabine Blum and Rita Mitnacht-Kraus and Dijkman, {Henry B P M} and Levent Kanal and {De Waal}, {Robert M W} and Matthias Clauss",
year = "2003",
month = "10",
day = "20",
doi = "10.1002/ijc.11345",
language = "English",
volume = "107",
pages = "30--37",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis

AU - Matschurat, Susanne

AU - Blum, Sabine

AU - Mitnacht-Kraus, Rita

AU - Dijkman, Henry B P M

AU - Kanal, Levent

AU - De Waal, Robert M W

AU - Clauss, Matthias

PY - 2003/10/20

Y1 - 2003/10/20

N2 - Tissue factor is the prime initiator of blood coagulation. Expression of tissue factor in tumor endothelial cells leads to thrombus formation, occlusion of vessels and development of hemorrhagic infarctions in the tumor tissue, often followed by regression of the tumor. Tumor cells produce endogenous vascular endothelial growth factor (VEGF), which sensitizes endothelial cells for systemically administered tumor necrosis factor α (TNF α) and synergistically enhances the TNF-induced expression of tissue factor. We have analyzed the pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells (HUVECS) after combined stimulation with TNF and VEGF. By using specific low molecular weight inhibitors, we demonstrated that protein kinase C (PKC), p44/42 and p38 mitogen-activated protein (MAP) kinases, and stress-activated protein kinase (JNK) are essentially involved in the induction of tissue factor. In contrast, the application of wortmannin, an inhibitor of phosphatidylinositol 3 (PI3)-kinase, led to strongly enhanced expression of tissue factor in TNF- and VEGF-treated cells, implicating a negative regulatory role for PI3-kinase. In vivo, the application of wortmannin promoted the formation of TNF-induced hemorrhages and intratumoral necroses in murine meth A tumors. The co-injection of wortmannin lowered the effective dose of applied TNF. Therefore, it is conceivable that the treatment of TNF-sensitive tumors with a combination of TNF and wortmannin will ensure the selective damage of the tumor endothelium and minimize the risk of systemic toxicity of TNF. TNF-treatment in combination with specific inhibition of PI3-kinase is a novel concept in anti-cancer therapy.

AB - Tissue factor is the prime initiator of blood coagulation. Expression of tissue factor in tumor endothelial cells leads to thrombus formation, occlusion of vessels and development of hemorrhagic infarctions in the tumor tissue, often followed by regression of the tumor. Tumor cells produce endogenous vascular endothelial growth factor (VEGF), which sensitizes endothelial cells for systemically administered tumor necrosis factor α (TNF α) and synergistically enhances the TNF-induced expression of tissue factor. We have analyzed the pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells (HUVECS) after combined stimulation with TNF and VEGF. By using specific low molecular weight inhibitors, we demonstrated that protein kinase C (PKC), p44/42 and p38 mitogen-activated protein (MAP) kinases, and stress-activated protein kinase (JNK) are essentially involved in the induction of tissue factor. In contrast, the application of wortmannin, an inhibitor of phosphatidylinositol 3 (PI3)-kinase, led to strongly enhanced expression of tissue factor in TNF- and VEGF-treated cells, implicating a negative regulatory role for PI3-kinase. In vivo, the application of wortmannin promoted the formation of TNF-induced hemorrhages and intratumoral necroses in murine meth A tumors. The co-injection of wortmannin lowered the effective dose of applied TNF. Therefore, it is conceivable that the treatment of TNF-sensitive tumors with a combination of TNF and wortmannin will ensure the selective damage of the tumor endothelium and minimize the risk of systemic toxicity of TNF. TNF-treatment in combination with specific inhibition of PI3-kinase is a novel concept in anti-cancer therapy.

KW - Anti-tumor therapy

KW - PI3-kinase

KW - Tissue factor

KW - Tumor necrosis factor

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0041914316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041914316&partnerID=8YFLogxK

U2 - 10.1002/ijc.11345

DO - 10.1002/ijc.11345

M3 - Article

VL - 107

SP - 30

EP - 37

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -